- Home
- CHRS vs FENC Comparison
CHRS vs FENC Comparison
Compare CHRS & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- FENC
- Stock Information
- Founded
- CHRS 2010
- FENC 1996
- Country
- CHRS United States
- FENC United States
- Employees
- CHRS N/A
- FENC N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CHRS Health Care
- FENC Health Care
- Exchange
- CHRS Nasdaq
- FENC Nasdaq
- Market Cap
- CHRS 191.3M
- FENC 172.8M
- IPO Year
- CHRS 2014
- FENC 2001
- Fundamental
- Price
- CHRS $1.47
- FENC $5.82
- Analyst Decision
- CHRS Strong Buy
- FENC Strong Buy
- Analyst Count
- CHRS 4
- FENC 2
- Target Price
- CHRS $5.38
- FENC $14.00
- AVG Volume (30 Days)
- CHRS 2.3M
- FENC 81.3K
- Earning Date
- CHRS 11-06-2024
- FENC 11-07-2024
- Dividend Yield
- CHRS N/A
- FENC N/A
- EPS Growth
- CHRS N/A
- FENC N/A
- EPS
- CHRS N/A
- FENC N/A
- Revenue
- CHRS $304,340,000.00
- FENC $49,348,000.00
- Revenue This Year
- CHRS $2.47
- FENC $107.12
- Revenue Next Year
- CHRS N/A
- FENC $33.37
- P/E Ratio
- CHRS N/A
- FENC N/A
- Revenue Growth
- CHRS 44.19
- FENC 278.09
- 52 Week Low
- CHRS $0.66
- FENC $3.96
- 52 Week High
- CHRS $2.97
- FENC $11.49
- Technical
- Relative Strength Index (RSI)
- CHRS 50.55
- FENC 46.53
- Support Level
- CHRS $1.35
- FENC $6.00
- Resistance Level
- CHRS $1.77
- FENC $6.19
- Average True Range (ATR)
- CHRS 0.13
- FENC 0.29
- MACD
- CHRS -0.02
- FENC -0.08
- Stochastic Oscillator
- CHRS 28.57
- FENC 12.93
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.